Literature DB >> 16002699

Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.

Peter J Darlington1, Mark G Kirchhof, Gabriel Criado, Jitin Sondhi, Joaquín Madrenas.   

Abstract

CTLA-4 is an activation-induced, homodimeric inhibitory receptor in T cells. Recent crystallographic reports have suggested that it may form lattice-like arrays on the cell surface upon binding B7.1/B7.2 (CD80, CD86) molecules. To test the biological relevance of these CTLA-4-B7 lattices, we introduced a C122A point mutation in human CTLA-4, because this residue was shown to be essential for dimerization in solution. Surprisingly, we found that up to 35% of C122A CTLA-4 dimerized in human T lymphocytes. Moreover, C122A CTLA-4 partitioned within lipid rafts, colocalized with the TCR in the immunological synapse, and inhibited T cell activation. C122-independent dimerization of CTLA-4 involved N-glycosylation, because further mutation of the N78 and N110 glycosylation sites abrogated dimerization. Despite being monomeric, the N78A/N110A/C122A triple mutant CTLA-4 localized in the immunological synapse and inhibited T cell activation. Such functionality correlated with B7-induced dimerization of these mutant molecules. Based on these data, we propose a model of hierarchical regulation of CTLA-4 oligomerization by which B7 binding ultimately determines the formation of dimer-dependent CTLA-4 lattices that may be necessary for triggering B7-dependent T cell inactivation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002699     DOI: 10.4049/jimmunol.175.2.996

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.

Authors:  Andreas Herrmann; Saul J Priceman; Piotr Swiderski; Maciej Kujawski; Hong Xin; Gregory A Cherryholmes; Wang Zhang; Chunyan Zhang; Christoph Lahtz; Claudia Kowolik; Steve J Forman; Marcin Kortylewski; Hua Yu
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 2.  Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.

Authors:  Austin W T Chiang; Hratch M Baghdassarian; Benjamin P Kellman; Bokan Bao; James T Sorrentino; Chenguang Liang; Chih-Chung Kuo; Helen O Masson; Nathan E Lewis
Journal:  J Biomed Sci       Date:  2021-06-22       Impact factor: 8.410

3.  Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.

Authors:  Laura Esposito; Kara M D Hunter; Jan Clark; Daniel B Rainbow; Helen Stevens; Jennifer Denesha; Simon Duley; Sarah Dawson; Gillian Coleman; Sarah Nutland; Gwynneth L Bell; Carla Moran; Marcin Pekalski; John A Todd; Linda S Wicker
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

Review 4.  Confusing signals: recent progress in CTLA-4 biology.

Authors:  Lucy S K Walker; David M Sansom
Journal:  Trends Immunol       Date:  2015-01-09       Impact factor: 16.687

5.  Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.

Authors:  Maud Condomines; Jon Arnason; Reuben Benjamin; Gertrude Gunset; Jason Plotkin; Michel Sadelain
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

6.  An Integrative Network Modeling Approach to T CD4 Cell Activation.

Authors:  David Martínez-Méndez; Carlos Villarreal; Luis Mendoza; Leonor Huerta
Journal:  Front Physiol       Date:  2020-04-23       Impact factor: 4.566

7.  N-Glycosylation Facilitates 4-1BB Membrane Localization by Avoiding Its Multimerization.

Authors:  Ruoxuan Sun; Alyssa Min Jung Kim; Allison A Murray; Seung-Oe Lim
Journal:  Cells       Date:  2022-01-04       Impact factor: 6.600

8.  Continuous Modeling of T CD4 Lymphocyte Activation and Function.

Authors:  David Martínez-Méndez; Luis Mendoza; Carlos Villarreal; Leonor Huerta
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

9.  Structure-Function analysis of the CTLA-4 interaction with PP2A.

Authors:  Wendy A Teft; Thu A Chau; Joaquín Madrenas
Journal:  BMC Immunol       Date:  2009-04-30       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.